The Pune-based National Institute of Virology (NIV) has developed the kit, known as a multiplex single tube realtime RT-PCR test.

The National Institute of Virology has developed the first indigenous testing kit to detect three infections—Influenza A, B and SARS-CoV-2—through a single kit, and wants interested companies to take it to the mass market.

The kit is what is known as a multiplex single tube realtime RT-PCR test to detect Influenza A, B and Covid-19, said Dr Varsha Potdar, head of NIV Pune’s influenza division.

“This will be an easy, time saving and efficient way of detecting three infections through a single test,” she said. “Single tube essentially means that using a person’s single sample, we will be able to diagnose multiple infections. Technicians will not have to test the sample separately.”

Symptoms of the three infections tend to overlap, making a kit such as this particularly useful during flu seasons.

The institute, a constituent of the Indian Council of Medical Research (ICMR), on May 15 invited expressions of interest (EoI) from companies to manufacture the kits in bulk, Dr Potdar said.

The test kit will use nasal and throat swabs of a patient, similar to the Covid-19 testing kits, but technicians will be able to use the sample for multiple disease detection, she added.

The institute now wants to hand over the technology to licensees or manufacturers “to enable them to commercialise the technology for societal benefit.”

“The company chosen shall undertake the scale-up as required, manufacturing and commercialiation of the technology and will share the technical data with ICMR,” the EoI document said.

Multiplex testing in molecular tests refers to polymerase chain reaction (PCR) tests that simultaneously detects multiple pathogens in a single reaction with a single sample.

While such technology is in different stages of development in various countries, this is the first indigenously developed kit that India will produce.

“We have set June 14 as the last date for companies to submit their interest,” Dr Potdar said. “Based on the applications we receive, we will evaluate the best candidate.”

The Centre for Disease Control and Prevention is also working on the Influenza SARS-CoV-2 (Flu SC2) Multiplex Assay, which is a real-time reverse-transcription PCR laboratory test that can simultaneously detect and differentiate between Influenza A, Influenza B, and SARS-CoV-2 in upper or lower respiratory specimens.

The test is a highly accurate, nucleic acid-based diagnostic tool to evaluate specimens from patients who are in the acute phase of infection, the centre said.

source/content: hindustantimes.com (headline edited)